Collegium Pharmaceutical, Inc. announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. This addition is part of the company's ongoing efforts to strengthen its governance and strategic oversight. Lurker's expertise is expected to be a valuable asset to Collegium.
Mike Heffernan, Founder and Chairman of the Board, stated that Lurker's experience in driving commercial growth and strategic acquisitions will be beneficial. This appointment supports Collegium's objective of building a diversified biopharmaceutical company. The company is focused on growing its commercial portfolio and deploying capital in a disciplined manner.
Lurker's background is particularly relevant as Collegium expands its presence in neuropsychiatry with Jornay PM. Her insights are expected to contribute to the company's strategy of maximizing its pain portfolio and accelerating momentum for its new growth drivers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.